Noel Unveils AI Cervical Cancer Diagnosis Solution at CES 2026

AI-based blood and cancer diagnostic company Noeul participated in CES 2026 held in Las Vegas, USA, where it unveiled its AI-based cervical cancer diagnostic solution. At this exhibition, Noeul showcased MyLab, a concept of a super compact all-in-one diagnostic laboratory. This product is equipped with features that allow AI to automatically analyze cells and interpret cancer stages. Notably, it is designed as a solution for on-site diagnostics. Im Chan-yang, CEO of Noeul, explained that this product minimizes the cell staining phase and achieves complete automation of the AI reading process, improving laboratory workflow to enable same-day testing and remote diagnostic services. Noeul plans to accelerate its entry into the North American market through this CES participation. They are meeting with healthcare professionals and investors on-site to discuss business collaborations. The company emphasized that the digital healthcare industry has evolved beyond simple monitoring to AI data analysis and support for medical operational efficiency after the pandemic, asserting that their technology aligns with this trend.